Author's response to reviews

Title: Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway

Authors:

Keinosuke Ryu (kei0202@nifty.com)
Michiro Susa (msusa@partners.org)
Edwin Choy (echoy@partners.org)
Cao Yang (cyang@partners.org)
Francis J Hornicek (fhornicek@partners.org)
Henry J Mankin (hmankin@partners.org)
Zhenfeng Duan (zduan@partners.org)

Version: 5 Date: 29 April 2010

Author's response to reviews: see over
Apr 29, 2010

The BMC Series Editorial Production Team

We appreciate the constructive comments and suggestions from both you and the reviewers regarding our manuscript, "Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway" (MS: 2018554733007574). We have edited the manuscript as journal style.

Major revisions (we require the author to make these changes)

Abstract: please ensure that the Abstract in the manuscript matches exactly what is in the submission system.

Response: We ensured that the Abstract in the manuscript matches exactly what is in the submission system.

Minor revisions (we can make these changes for you, although it will speed up publication of your manuscript if you do them while making the major changes above)

Email address: please include email addresses for all the authors on the title page, using the following format:

Response: We included email addresses for all the authors on the title page.

Figures: Please remove the figure numbers from the image files (but please leave 'A, B, C' etc in place).

Response: We removed the figure numbers from the image files.

Typography: Please take this opportunity to check your manuscript for any typographical errors and to make any final corrections or revisions. This is the final proofing stage for your manuscript, and you will not be able to make any changes after acceptance.

Response: We checked our manuscript.

We hope these changes will now make this manuscript acceptable for publication in BMC Cancer.
Respectfully,

Zhenfeng Duan